Abstract

BackgroundDurable ventricular assist device (VAD) therapy is reserved for patients with advanced heart failure who have a poor estimated 1-year survival. However, despite highly protocolized management processes, patients are at a unique risk for developing a health care–associated infection (HAI). Few studies have examined optimal strategies for HAI prevention after durable VAD implantation, despite variability in rates across centers and their impact on short- and long-term outcomes.ObjectiveThe objective of this study is to develop recommendations for preventing the most significant HAIs after durable VAD implantation. The study has 3 specific aims: (1) identify determinants of center-level variability in HAI rates, (2) develop comprehensive understanding of barriers and facilitators for achieving low center-level HAI rates, and (3) develop and disseminate a best practices toolkit for preventing HAIs that accommodates various center contexts.MethodsThis is a sequential mixed methods study starting with a cross-sectional assessment of current practices. To address aim 1, we will conduct (1) a systematic review of HAI prevention studies and (2) in-depth quantitative analyses using administrative claims, in-depth clinical data, and organizational surveys of VAD centers. For aim 2, we will apply a mixed methods patient tracer assessment framework to conduct semistructured interviews, field observations, and document analysis informed by findings from aim 1 at 5 high-performing (ie, low HAIs) and 5 low-performing (ie, high HAI) centers, which will be examined using a mixed methods case series analysis. For aim 3, we will build upon the findings from the previous aims to develop and field test an HAI preventive toolkit, acquire stakeholder input at an annual cardiac surgical conference, disseminate the final version to VAD centers nationwide, and conduct follow-up surveys to assess the toolkit’s adoption.ResultsThe project was funded by the Agency for Healthcare Research and Quality in 2018 and enrollment for the overall project is ongoing. Data analysis is currently under way and the first results are expected to be submitted for publication in 2019.ConclusionsThis mixed methods study seeks to quantitatively assess the determinants of HAIs across clinical centers and qualitatively identify the context-specific facilitators and barriers for attaining low HAI rates. The mixed data findings will be used to develop and disseminate a stakeholder-acceptable toolkit of evidence-based HAI prevention recommendations that will accommodate the specific contexts and needs of VAD centers.International Registered Report Identifier (IRRID)PRR1-10.2196/14701

Highlights

  • Use of Durable Ventricular Assist Device to Treat Advanced Heart FailureHeart failure affects nearly 5.7 million Americans and is a contributing cause of 1 in 9 deaths [1]

  • Durable ventricular assist device (VAD) therapy is reserved for patients with advanced heart failure who have a poor estimated 1-year survival [3,4]

  • In aim 1, we will (1) conduct a systematic review of existing health care–associated infection (HAI) prevention studies to compile a list of current prevention strategies and (2) conduct in-depth analyses using a unique merged dataset of all Food and Drug Administration (FDA)–approved VADs implanted in Medicare beneficiaries as well as an organizational survey administered to VAD centers

Read more

Summary

Introduction

Use of Durable Ventricular Assist Device to Treat Advanced Heart FailureHeart failure affects nearly 5.7 million Americans and is a contributing cause of 1 in 9 deaths [1]. Use of Durable Ventricular Assist Device to Treat Advanced Heart Failure. Technological advances using newer magnetically levitated centrifugal continuous-flow VADs have improved patient survival and decreased adverse event rates compared with older continuous-flow axial technology [5,6]. The estimated VAD survival is approximately 50% at 4 years, accompanied by significant improvements in functional status and quality of life [7,8]. Durable ventricular assist device (VAD) therapy is reserved for patients with advanced heart failure who have a poor estimated 1-year survival. Few studies have examined optimal strategies for HAI prevention after durable VAD implantation, despite variability in rates across centers and their impact on short- and long-term outcomes

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call